PMID- 35682884
OWN - NLM
STAT- MEDLINE
DCOM- 20220613
LR  - 20220716
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 23
IP  - 11
DP  - 2022 Jun 1
TI  - AMPK and the Challenge of Treating Hypoxic Pulmonary Hypertension.
LID - 10.3390/ijms23116205 [doi]
LID - 6205
AB  - Hypoxic pulmonary hypertension (HPH) is characterized by sustained elevation of 
      pulmonary artery pressure produced by vasoconstriction and hyperproliferative 
      remodeling of the pulmonary artery and subsequent right ventricular hypertrophy 
      (RVH). The search for therapeutic targets for cardiovascular pathophysiology has 
      extended in many directions. However, studies focused on mitigating high-altitude 
      pulmonary hypertension (HAPH) have been rare. Because AMP-activated protein 
      kinase (AMPK) is involved in cardiovascular and metabolic pathology, AMPK is 
      often studied as a potential therapeutic target. AMPK is best characterized as a 
      sensor of cellular energy that can also restore cellular metabolic homeostasis. 
      However, AMPK has been implicated in other pathways with vasculoprotective 
      effects. Notably, cellular metabolic stress increases the intracellular ADP/ATP 
      or AMP/ATP ratio, and AMPK activation restores ATP levels by activating 
      energy-producing catabolic pathways and inhibiting energy-consuming anabolic 
      pathways, such as cell growth and proliferation pathways, promoting 
      cardiovascular protection. Thus, AMPK activation plays an important role in 
      antiproliferative, antihypertrophic and antioxidant pathways in the pulmonary 
      artery in HPH. However, AMPK plays contradictory roles in promoting HPH 
      development. This review describes the main findings related to AMPK 
      participation in HPH and its potential as a therapeutic target. It also 
      extrapolates known AMPK functions to discuss the less-studied HAPH context.
FAU - Flores, Karen
AU  - Flores K
AD  - Institute of Health Studies, University Arturo Prat, Av. Arturo Prat 2120, 
      Iquique 1110939, Chile.
AD  - Institute DECIPHER, German-Chilean Institute for Research on Pulmonary Hypoxia 
      and Its Health Sequelae, 20251 Hamburg, Germany and Iquique 1100000, Chile.
FAU - Siques, Patricia
AU  - Siques P
AUID- ORCID: 0000-0002-4963-195X
AD  - Institute of Health Studies, University Arturo Prat, Av. Arturo Prat 2120, 
      Iquique 1110939, Chile.
AD  - Institute DECIPHER, German-Chilean Institute for Research on Pulmonary Hypoxia 
      and Its Health Sequelae, 20251 Hamburg, Germany and Iquique 1100000, Chile.
FAU - Brito, Julio
AU  - Brito J
AUID- ORCID: 0000-0002-0050-8774
AD  - Institute of Health Studies, University Arturo Prat, Av. Arturo Prat 2120, 
      Iquique 1110939, Chile.
AD  - Institute DECIPHER, German-Chilean Institute for Research on Pulmonary Hypoxia 
      and Its Health Sequelae, 20251 Hamburg, Germany and Iquique 1100000, Chile.
FAU - Arribas, Silvia M
AU  - Arribas SM
AD  - Department of Physiology, University Autonoma of Madrid, 28049 Madrid, Spain.
LA  - eng
GR  - BIP30477541-0 / BIP30487388-0/GORE-FIC TARAPACA BIP30477541-0 / GORE-FIC TARAPACA 
      BIP30487388-0/
PT  - Journal Article
PT  - Review
DEP - 20220601
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 8L70Q75FXE (Adenosine Triphosphate)
RN  - EC 2.7.11.31 (AMP-Activated Protein Kinases)
RN  - Pulmonary edema of mountaineers
SB  - IM
MH  - *AMP-Activated Protein Kinases/metabolism
MH  - Adenosine Triphosphate
MH  - Altitude Sickness
MH  - Humans
MH  - *Hypertension, Pulmonary/drug therapy/etiology/pathology
MH  - Hypoxia
MH  - Pulmonary Artery/pathology
PMC - PMC9181235
OTO - NOTNLM
OT  - AMPK
OT  - cardioprotection
OT  - high altitude
OT  - hypoxic pulmonary hypertension
COIS- The authors declare no conflict of interest.
EDAT- 2022/06/11 06:00
MHDA- 2022/06/14 06:00
PMCR- 2022/06/01
CRDT- 2022/06/10 01:15
PHST- 2022/03/29 00:00 [received]
PHST- 2022/04/29 00:00 [revised]
PHST- 2022/04/30 00:00 [accepted]
PHST- 2022/06/10 01:15 [entrez]
PHST- 2022/06/11 06:00 [pubmed]
PHST- 2022/06/14 06:00 [medline]
PHST- 2022/06/01 00:00 [pmc-release]
AID - ijms23116205 [pii]
AID - ijms-23-06205 [pii]
AID - 10.3390/ijms23116205 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Jun 1;23(11):6205. doi: 10.3390/ijms23116205.